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Background
In light of solid data regarding the extent of the placebo
response as well as the rigorous arguments in favor of
the randomized, placebo-controlled clinical trial, placebo
analgesia has widely been tested and documented as one
of the most robust placebo effects. Newly developed
brain imaging tools such as functional magnetic
resonance imaging (fMRI) have provided systematic
evidence for the neurophysiological substrates involved
in placebo analgesia [1,2].
Materials and methods
In the present study, the replication of a well-documented
expectancy manipulation model combined with a placebo
intervention via acupuncture [3] was conducted to deter-
mine neural mechanisms underlying placebo analgesia in a
group of 12 patients (6 females; mean age, 38.4 +/- 4.5 SD)
with progressive multiple sclerosis (MS) matched for age,
sex, duration of disease, disability and subjective pain
ratings. Procedures involved two behavioral testing ses-
sions and one fMRI scanning session as well as the admin-
istration of expectancy and pain subjective rating scales.
Results
Subjective pain ratings indicated a significantly greater
reduction in the placebo-control group as compared to
the untreated condition (before/after treatment). The
functional MRI signal difference between post-treatment
and pre-treatment sessions was subtracted from the
same difference in the non-treatment control group
(post- and pre- placebo phases and post- and
pre- control phases) indicating significant changes in
mainly two of the so-called pain-sensitive brain regions
such as the bilateral rostral anterior cingulated cortex
(rACC) and the lateral prefrontal cortex.
Conclusions
Such findings are not consistent with research data from a
wide range of neuropathies utilizing variant placebo treat-
ments [4], suggesting that placebo analgesia as a result of
expectancy can be detected in progressive multiple sclero-
sis yet, be subserved by the aforementioned brain regions.
Future directions involve the study of brain activation
patterns as a function of modality of placebo treatments
with analgesic effects and identifying MS-specific forms of
confounding as related to placebo analgesia.
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